Degradation of Erythromycin by a Novel Fungus, Penicillium oxalicum RJJ-2, and the Degradation Pathway

Ren, Jianjun; Wang, Zhenzhu; Deng, Liujie; Niu, Dongze; Huhetaoli,; Li, Zhijie; Zhang, Jin; Zhang, Ruitao; Li, Chunyu

doi:10.1007/s12649-021-01343-y

Cited by 11 publications

(4 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The erythromycin could eventually be degraded to a concentration of about 20 mg·L −1 , regardless of the initial substrate concentration; the half-life of erythromycin was about 100 min. Such degradability is better than that reported for other erythromycin treatment methods [ 9 , 11 , 31 , 33 ]. Therefore, the enhanced tolerance and reusability increased the potential for utilizing the enzyme in harsh conditions.…”

Section: Resultsmentioning

confidence: 57%

See 1 more Smart Citation

Immobilization of EreB on Acid-Modified Palygorskite for Highly Efficient Degradation of Erythromycin

et al. 2022

IJERPH

Self Cite

View full text Add to dashboard Cite

Erythromycin is one of the most commonly used macrolide antibiotics. However, its pollution of the ecosystem is a significant risk to human health worldwide. Currently, there are no effective and environmentally friendly methods to resolve this issue. Although erythromycin esterase B (EreB) specifically degrades erythromycin, its non-recyclability and fragility limit the large-scale application of this enzyme. In this work, palygorskite was selected as a carrier for enzyme immobilization. The enzyme was attached to palygorskite via a crosslinking reaction to construct an effective erythromycin-degradation material (i.e., EreB@modified palygorskite), which was characterized using FT-IR, SEM, XRD, and Brunauer–Emmett–Teller techniques. The results suggested the successful modification of the material and the loading of the enzyme. The immobilized enzyme had a higher stability over varying temperatures (25–65 °C) and pH values (6.5–10.0) than the free enzyme, and the maximum rate of reaction (Vmax) and the turnover number (kcat) of the enzyme increased to 0.01 mM min−1 and 169 min−1, respectively, according to the enzyme-kinetics measurements. The EreB@modified palygorskite maintained about 45% of its activity after 10 cycles, and degraded erythromycin in polluted water to 20 mg L−1 within 300 min. These results indicate that EreB could serve as an effective immobilizing carrier for erythromycin degradation at the industrial scale.

show abstract

Section: Resultsmentioning

confidence: 57%

“…The mobile phase was acetonitrile and K 2 HPO 4 (0.01 M) at a ratio of 55:45 ( v/v ) and a flow rate of 1 mL·min −1 . A variable-wavelength UV detector was set at 215 nm [ 33 ].…”

Section: Methodsmentioning

confidence: 99%

Immobilization of EreB on Acid-Modified Palygorskite for Highly Efficient Degradation of Erythromycin

et al. 2022

IJERPH

Self Cite

View full text Add to dashboard Cite

show abstract

“…93 Different microbial remediation studies on the removal efficiency of pharmaceutical pollutants are listed in Table 3. 95–119…”

Section: Microbial Degradationmentioning

confidence: 99%

Promising approaches and kinetic prospects of the microbial degradation of pharmaceutical contaminants

Karishma,

Yaashikaa,

Kumar

et al. 2023

Environ. Sci.: Adv.

View full text Add to dashboard Cite

show abstract

“…The filamentous fungi Penicillium commune , Epicoccum nigrum , T. harzianum , Aspergillus terreus , and Beauveria bassiana were identified as having the best remediation rates amounting to a maximum of 78% removal of a 250 mg/L oxytetracycline concentration in flask experiments ( Ahumada-Rudolph et al, 2021 ). P. oxalicum RJJ-2 has also been studied in the degradation of erythromycin and degraded 84.88% erythromycin after 96-h incubation used as the sole carbon source producing different metabolites ( Ren et al, 2021 ).…”

Section: Development Of Bioremediation Technologiesmentioning

confidence: 99%

Pharmaceutical Pollution in Aquatic Environments: A Concise Review of Environmental Impacts and Bioremediation Systems

et al. 2022

View full text Add to dashboard Cite

The presence of emerging contaminants in the environment, such as pharmaceuticals, is a growing global concern. The excessive use of medication globally, together with the recalcitrance of pharmaceuticals in traditional wastewater treatment systems, has caused these compounds to present a severe environmental problem. In recent years, the increase in their availability, access and use of drugs has caused concentrations in water bodies to rise substantially. Considered as emerging contaminants, pharmaceuticals represent a challenge in the field of environmental remediation; therefore, alternative add-on systems for traditional wastewater treatment plants are continuously being developed to mitigate their impact and reduce their effects on the environment and human health. In this review, we describe the current status and impact of pharmaceutical compounds as emerging contaminants, focusing on their presence in water bodies, and analyzing the development of bioremediation systems, especially mycoremediation, for the removal of these pharmaceutical compounds with a special focus on fungal technologies.

show abstract

Degradation of Erythromycin by a Novel Fungus, Penicillium oxalicum RJJ-2, and the Degradation Pathway

Cited by 11 publications

References 29 publications

Immobilization of EreB on Acid-Modified Palygorskite for Highly Efficient Degradation of Erythromycin

Immobilization of EreB on Acid-Modified Palygorskite for Highly Efficient Degradation of Erythromycin

Promising approaches and kinetic prospects of the microbial degradation of pharmaceutical contaminants

Pharmaceutical Pollution in Aquatic Environments: A Concise Review of Environmental Impacts and Bioremediation Systems

Contact Info

Product

Resources

About